Get the Stockscreener App
295.30
0.47%
1.38
After Hours:
295.95
0.65
+0.22%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Amgen Inc stock is traded at $295.30, with a volume of 2.59M.
It is up +0.47% in the last 24 hours and down -5.87% over the past month.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
See More
Previous Close:
$293.92
Open:
$294.305
24h Volume:
2.59M
Relative Volume:
0.85
Market Cap:
$158.64B
Revenue:
$33.42B
Net Income/Loss:
$4.09B
P/E Ratio:
39.11
EPS:
7.55
Net Cash Flow:
$10.39B
1W Performance:
+5.37%
1M Performance:
-5.87%
6M Performance:
-9.16%
1Y Performance:
+11.22%
1-Day Range:
$292.14
$296.17
1-Week Range:
$267.40
$296.17
52-Week Range:
$253.30
$346.85
Amgen Inc Stock (AMGN) Company Profile
Name
Amgen Inc
Sector
Industry
Phone
(805)447-1000
Address
ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA
Compare AMGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AMGN
Amgen Inc
|
295.30 | 158.64B | 33.42B | 4.09B | 10.39B | 7.55 |
|
LLY
Lilly Eli Co
|
757.18 | 680.08B | 45.04B | 10.59B | 414.30M | 11.71 |
|
JNJ
Johnson Johnson
|
153.62 | 344.63B | 88.82B | 14.07B | 18.06B | 5.79 |
|
ABBV
Abbvie Inc
|
176.80 | 312.76B | 56.33B | 4.28B | 17.83B | 2.40 |
|
NVO
Novo Nordisk Adr
|
64.49 | 286.27B | 42.09B | 14.65B | 10.11B | 3.2833 |
|
NVS
Novartis Ag Adr
|
109.93 | 217.12B | 51.72B | 11.94B | 13.81B | 5.88 |
Amgen Inc Stock (AMGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Oct-14-24 | Downgrade | Truist | Buy → Hold |
| Sep-27-24 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-07-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| May-03-24 | Upgrade | Barclays | Underweight → Equal Weight |
| May-03-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Mar-28-24 | Resumed | Raymond James | Mkt Perform |
| Feb-07-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Dec-21-23 | Upgrade | Daiwa Securities | Neutral → Buy |
| Dec-19-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Dec-12-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-02-23 | Upgrade | Truist | Hold → Buy |
| Oct-20-23 | Resumed | JP Morgan | Neutral |
| Oct-17-23 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-11-23 | Resumed | BofA Securities | Neutral |
| Sep-06-23 | Initiated | HSBC Securities | Buy |
| Apr-24-23 | Reiterated | Oppenheimer | Outperform |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Feb-13-23 | Reiterated | Truist | Buy |
| Nov-18-22 | Initiated | Credit Suisse | Underperform |
| Oct-31-22 | Downgrade | Barclays | Equal Weight → Underweight |
| Oct-11-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Feb-09-22 | Reiterated | Barclays | Equal Weight |
| Feb-09-22 | Reiterated | Jefferies | Buy |
| Feb-09-22 | Reiterated | Morgan Stanley | Equal-Weight |
| Feb-09-22 | Reiterated | Oppenheimer | Outperform |
| Feb-09-22 | Reiterated | Wells Fargo | Equal Weight |
| Jan-05-22 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Dec-06-21 | Initiated | Goldman | Buy |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Sep-23-21 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Sep-07-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-29-20 | Initiated | Daiwa Securities | Buy |
| Oct-28-20 | Initiated | UBS | Neutral |
| Oct-26-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Oct-12-20 | Upgrade | Truist | Hold → Buy |
| Oct-09-20 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Oct-09-20 | Downgrade | Truist | Buy → Hold |
| Oct-08-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Apr-15-20 | Resumed | Guggenheim | Neutral |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Mar-30-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Mar-05-20 | Upgrade | BofA/Merrill | Neutral → Buy |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Jan-31-20 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Jan-21-20 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-24-19 | Initiated | Raymond James | Mkt Perform |
| Dec-17-19 | Resumed | Morgan Stanley | Overweight |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Nov-05-19 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Aug-19-19 | Downgrade | Mizuho | Buy → Neutral |
| May-23-19 | Upgrade | Citigroup | Neutral → Buy |
View All
Amgen Inc Stock (AMGN) Latest News
Alston & Bird Allege Big Pharma Company Amgen Monopolized US Arthritis Drug Market - Law.com
HHS Rejects Amgen, Lilly Fight of Clinics in Drug Discount Plan - Bloomberg Law News
Lobbying Update: $60,000 of AMGEN INC lobbying was just disclosed - Nasdaq
Savvy Advisors Inc. Buys 2,087 Shares of Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Bragg Financial Advisors Inc Decreases Stock Position in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Stamos Capital Partners L.P. Boosts Stock Holdings in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Townsquare Capital LLC Has $8.38 Million Position in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
RE Dickinson Investment Advisors LLC Decreases Stock Holdings in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Sagespring Wealth Partners LLC Invests $3.78 Million in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
EPO and UPC disagree on validity of Amgen’s patent for cholesterol drug - JUVE Patent
Renaissance Technologies LLC Invests $18 Million in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Zuckerman Investment Group LLC Invests $521,000 in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Argent Trust Co Lowers Holdings in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Azimuth Capital Investment Management LLC Cuts Stock Position in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Legacy Financial Advisors Inc. Acquires 948 Shares of Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Clinical Trial Optimization - Amgen
Human & Disease Biology - Amgen
Novel Targets & Modalities - Amgen
Treasurer of the State of North Carolina Buys 1,291 Shares of Amgen Inc. (NASDAQ:AMGN) - MarketBeat
FDA Approval of Amgen's UPLIZNA for IgG4-related Disease Opens New Market Opportunity in Rare Autoimmune Segment | DelveInsight - Yahoo Finance
Sandoz Sues Amgen Over Alleged Monopoly Tactics - USA Herald
Sandoz Sues Amgen Over Enbrel Biosimilar - Law360
Sector Update: Health Care Stocks Rise Monday Afternoon - MarketScreener
Sandoz sues Amgen over nine-year launch delay for Enbrel biosimilar - Endpoints News
Sandoz files U.S. antitrust lawsuit against Amgen over arthritis drug - Reuters
India Immuno-Oncology Drugs Market Set to Witness Significant - openPR.com
Sandoz Files Lawsuit Alleging Amgen Illegally Blocked Biosimilar Competition For Its Blockbuster Arthritis Drug - Benzinga
Amgen’s Imdelltra Sets The Pace In Small-Cell Lung Cancer - insights.citeline.com
Sandoz Files Antitrust Lawsuit Against Amgen Over Biosimilar Blockade - TipRanks
Sandoz sues Amgen in the US - MarketScreener
[Corrected] Sandoz files antitrust litigation against Amgen regarding patient access to etanercept biosimilar in the US - The Manila Times
Sandoz Attacks Amgen Over US Enbrel Exclusivity - insights.citeline.com
UBS Adjusts Amgen (AMGN) Price Target to $319, Maintains Neutral - GuruFocus
Amgen’s Imdelltra shows significant survival benefit in SCLC - World Pharmaceutical Frontiers
Amgen faces antitrust lawsuit from Sandoz over Enbrel patents - Seeking Alpha
Sandoz challenges Amgen’s Enbrel patents in US antitrust lawsuit - Yahoo Finance
Jaffetilchin Investment Partners LLC Buys 1,775 Shares of Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Petros Family Wealth LLC Takes Position in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Sterling Capital Management LLC Sells 10,554 Shares of Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Sandoz sues Amgen in US for blocking biosimilar rivals - MLex
LSV Asset Management Sells 470,060 Shares of Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Sandoz files lawsuit against Amgen regarding etanercept biosimilar in the USA - The Pharma Letter
Sandoz (SDZNY) Files Antitrust Lawsuit Against Amgen Over Market Control | AMGN Stock News - GuruFocus
Arthritis drug: Sandoz files US antitrust litigation against Amgen - Medical Dialogues
Swiss Drugmaker Sandoz Takes Amgen to Court for Blocking US Entry of Enbrel Biosimilar - MarketScreener
Amgen’s Phase III trial of Imdelltra meets primary endpoint for SCLC - Clinical Trials Arena
Switzerland’s Sandoz files antitrust lawsuit against Amgen in US - 1470 & 100.3 WMBD
Amgen’s Big Bet on Obesity: Is This the Pharma Giant’s Next Breakout Moment? - Smartkarma
Sandoz Sues Amgen for Blocking Competition in US from Biosimilars for Enbrel - MarketScreener
Amgen (NASDAQ:AMGN) Shares Gap DownHere's What Happened - MarketBeat
Sandoz files antitrust litigation against Amgen regarding patient access to etanercept biosimilar in the US - The Manila Times
Amgen Inc Stock (AMGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.77%
1.45%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):